|
KR20210018316A
|
|
Anti-SEZ6 antibody drug conjugate and method of use
|
|
US2019225685A1
|
|
Anti-dll3 antibody drug conjugates and methods of use
|
|
WO2018213680A1
|
|
Diagnostic antibodies and methods of use
|
|
WO2018107109A1
|
|
Novel anti-kremen2 antibodies and methods of use
|
|
WO2018107116A1
|
|
Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
|
|
WO2017201440A1
|
|
Anti-ascl1 antibodies and methods of use
|
|
WO2017201442A1
|
|
Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transition
|
|
EP3452511A1
|
|
Novel anti-tnfrsf21 antibodies and methods of use
|
|
AU2017254674A1
|
|
Novel anti-BMPR1B antibodies and methods of use
|
|
EP3394107A1
|
|
Novel anti-tnfsf9 antibodies and methods of use
|
|
US2019000969A1
|
|
Novel anti-upk1b antibodies and methods of use
|
|
CA3009484A1
|
|
Novel anti-mmp16 antibodies and methods of use
|
|
BR112018011319A2
|
|
new anti-claudin antibodies and methods of use
|
|
EP3377079A1
|
|
Novel anti-emr2 antibodies and methods of use
|
|
TW201718026A
|
|
Anti-DLL3 antibody drug conjugates and methods of use
|
|
KR20170139110A
|
|
Calicheamicin constructs and methods of use
|
|
US2018112004A1
|
|
Engineered site-specific antibodies and methods of use
|
|
KR20170120158A
|
|
Anti-DLL3 chimeric antigen receptors and methods for their use
|
|
CA2966618A1
|
|
Anti-cldn chimeric antigen receptors and methods of use
|
|
AU2015249887A1
|
|
Novel anti-RNF43 antibodies and methods of use
|
